Friday, September 30, 2016 4:44:10 PM
Total Revenue 5,788.177 3,317.039 4,095.907
Cost of Revenue 4,268.743 2,682.399 3,895.091
Gross Profit 1,519.434 634.64 200.816
Operating Expenses
Research Development - - -
Selling General and Administrative 1,322.36 1,916.511 828.148
Non Recurring - - 406.211
Others - - -
Total Operating Expenses - - -
Operating Income or Loss 197.074 -1,281.871 -1,033.543
Income from Continuing Operations
Total Other Income/Expenses Net 1.438 2.213 1,812.724
Earnings Before Interest and Taxes 198.512 -1,279.658 779.181
Interest Expense 2.701 4.67 14.806
Income Before Tax 195.811 -1,284.328 764.375
Income Tax Expense - - -
Minority Interest - - -
Net Income From Continuing Ops 195.811 -1,284.328 764.375
Non-recurring Events
Discontinued Operations - - -
Extraordinary Items - - -
Effect Of Accounting Changes - - -
Other Items - - -
Net Income
Net Income 195.811 -1,284.328 764.375
Preferred Stock And Other Adjustments - - -
Net Income Applicable To Common Shares 195.811 -1,284.328 764.375
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM